Skip to content Skip to footer
Subscribe Now
NEWS

Eli Lilly to Acquire Ventyx for ~$1.2B

Shots: Eli Lilly has entered into a definitive agreement to acquire Ventyx, strengthening Lilly’s capabilities in inflammatory-mediated diseases As per the deal, Eli Lilly will acquire Ventyx for $14/share in an all-cash transaction, representing an aggregate equity value of ~$1.2B; closing is expected in H1’26 Ventyx is advancing a pipeline of oral small-molecule therapies, incl.…
January 8, 2026

Read more

NEWS

Nimbus Therapeutics and Eli Lilly Enter ~$1.3B Deal to Develop Oral Metabolic Therapies

Shots: Nimbus has entered into a multi-year research collaboration & exclusive, worldwide license agreement with Eli Lilly to develop a novel oral treatment for obesity & other metabolic diseases Building on their prior AMPK cardiometabolic collaboration, Nimbus & Lilly have entered into a new partnership applying Nimbus’ computational chemistry & structure-based design to an…
January 7, 2026

Read more

NEWS

ABL Bio Secures Upfront Payment and Equity Investment from Lilly to Accelerate Grabody Programs 

Shots: ABL Bio has secured a total of $55M, incl. $40M upfront & $15M in equity investment, from Eli Lilly under their ~$2.602B license, research & collaboration agreement Under the deal, ABL Bio & Eli Lilly are jointly advancing multiple therapeutic candidates across diverse modalities, leveraging ABL Bio’s Grabody platform for collaborative research & development…
December 29, 2025

Read more

Eli lilly
NEWS

Eli Lilly Reports Topline P-III (ATTAIN-MAINTAIN) Trial Results of Orforglipron for Weight Loss Maintenance 

Shots: Lilly's P-III trial assessed orforglipron vs PBO in maintaining weight loss in 376 adults with obesity/overweight & weight-related comorbidities who previously completed the initial treatment with Wegovy/Zepbound in the SURMOUNT-5 trial; NDA was submitted to FDA & received a US FDA’s CNPV Trial met its 1EP in SURMOUNT-5 pts at a weight plateau, showing superior…
December 19, 2025

Read more

Eli lilly
NEWS

Eli Lilly Reports P-III (BRUIN CLL-313) Trial Data on Jaypirca for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Shots: Eli Lilly has reported P-III (BRUIN CLL-313) trial data assessing Jaypirca (pirtobrutinib; 200mg, PO, QD; n=141) vs bendamustine + rituximab (n=141) in 282 treatment-naïve CLL/SLL pts without 17p deletions As of Jul 11, 2025, trial met its 1EP of improved IRC-assessed PFS by 80% with benefits seen across all high-risk subgroups & investigator assessments at…
December 10, 2025

Read more

Eli lilly
NEWS

Eli Lilly’s Jaypirca Receives the FDA Approval for R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

Shots: The US FDA has approved label expansion of Jaypirca (pirtobrutinib; 100 & 50mg) for the treatment of adults with r/r CLL/SLL who were previously treated with a covalent BTK inhibitor & converted the accelerated approval of Dec 2023 to a full approval Label expansion was based on the P-III (BRUIN CLL-321) study assessing Jaypirca…
December 4, 2025

Read more

TOP 20

Top 20 Prescription Drugs of 2025 

Shots:  In 2025, the global Prescription Drugs market is projected to generate an impressive $1.13T, with steady annual growth of 3.94% expected through 2030, ultimately reaching $1.37T. Leading the pack is Keytruda, securing the first position with $29.48B, closely followed by Ozempic at $28.18B, and Eliquis, which recorded $20.69B in global sales. Fourth position is…
November 20, 2025

Read more

NEWS

SanegeneBio Collaborates with Eli Lilly to Advance RNAi Therapeutics for Metabolic Diseases

Shots: SanegeneBio has entered into a global research & licensing deal with Eli Lilly to advance RNAi candidates for metabolic diseases, leveraging SanegeneBio’s LEAD (Ligand & Enhancer Assisted Delivery) tech Under the deal, SanegeneBio will discover & identify LEAD-based RNAi molecules for each program, while Lilly will oversee IND-enabling studies, clinical development, & commercialization; the…
November 10, 2025

Read more

Load more